Cerus PE Ratio 2006-2019 | CERS

Current and historical p/e ratio for Cerus (CERS) from 2006 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Cerus PE ratio as of May 17, 2019 is 0.00.
Cerus PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-05-17 5.47 0.00
2019-03-31 6.23 $-0.33 0.00
2018-12-31 5.07 $-0.44 0.00
2018-09-30 7.21 $-0.42 0.00
2018-06-30 6.67 $-0.43 0.00
2018-03-31 5.48 $-0.49 0.00
2017-12-31 3.38 $-0.56 0.00
2017-09-30 2.73 $-0.59 0.00
2017-06-30 2.51 $-0.61 0.00
2017-03-31 4.45 $-0.63 0.00
2016-12-31 4.35 $-0.62 0.00
2016-09-30 6.21 $-0.64 0.00
2016-06-30 6.24 $-0.67 0.00
2016-03-31 5.93 $-0.66 0.00
2015-12-31 6.32 $-0.66 0.00
2015-09-30 4.54 $-0.76 0.00
2015-06-30 5.19 $-0.74 0.00
2015-03-31 4.17 $-0.73 0.00
2014-12-31 6.24 $-0.68 0.00
2014-09-30 4.01 $-0.53 0.00
2014-06-30 4.15 $-0.67 0.00
2014-03-31 4.80 $-0.60 0.00
2013-12-31 6.45 $-0.65 0.00
2013-09-30 6.72 $-0.62 0.00
2013-06-30 4.42 $-0.41 0.00
2013-03-31 4.42 $-0.42 0.00
2012-12-31 3.16 $-0.42 0.00
2012-09-30 3.40 $-0.51 0.00
2012-06-30 3.32 $-0.38 0.00
2012-03-31 4.02 $-0.41 0.00
2011-12-31 2.80 $-0.35 0.00
2011-09-30 2.12 $-0.25 0.00
2011-06-30 3.00 $-0.40 0.00
2011-03-31 2.91 $-0.41 0.00
2010-12-31 2.46 $-0.43 0.00
2010-09-30 3.84 $-0.50 0.00
2010-06-30 3.16 $-0.56 0.00
2010-03-31 2.79 $-0.61 0.00
2009-12-31 1.99 $-0.71 0.00
2009-09-30 2.19 $-0.78 0.00
2009-06-30 1.03 $-0.89 0.00
2009-03-31 0.68 $-0.98 0.00
2008-12-31 0.70 $-0.91 0.00
2008-09-30 4.13 $-1.07 0.00
2008-06-30 4.09 $-1.09 0.00
2008-03-31 5.77 $-1.37 0.00
2007-12-31 6.51 $-1.42 0.00
2007-09-30 8.73 $-0.96 0.00
2007-06-30 6.76 $-0.73 0.00
2007-03-31 6.75 $-0.35 0.00
2006-12-31 5.86 $-0.18 0.00
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.754B $0.061B
Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $134.025B 26.02
Medtronic (MDT) Ireland $117.659B 17.20
Stryker (SYK) United States $68.704B 24.52
Boston Scientific (BSX) United States $51.899B 24.88
Baxter (BAX) United States $38.763B 24.43
Zimmer Biomet Holdings (ZBH) United States $23.843B 15.32
Smith & Nephew SNATS (SNN) United Kingdom $18.247B 0.00
ResMed (RMD) United States $16.172B 30.90
Canopy Growth (CGC) Canada $15.352B 0.00
Bio-Rad Laboratories (BIO) United States $8.842B 46.88
Aurora Cannabis (ACB) Canada $8.802B 86.80
Perrigo (PRGO) Ireland $6.755B 11.42
Hill-Rom Holdings (HRC) United States $6.504B 19.72
Insulet (PODD) United States $6.200B 451.74
GW Pharmaceuticals (GWPH) United Kingdom $5.280B 0.00
Haemonetics (HAE) United States $5.104B 41.87
ICU Medical (ICUI) United States $4.630B 27.62
Hutchison China MediTech (HCM) China $3.565B 0.00
NuVasive (NUVA) United States $3.164B 25.84
Neogen (NEOG) United States $3.071B 49.94
Agios Pharmaceuticals (AGIO) United States $2.941B 0.00
Quidel (QDEL) United States $2.233B 23.17
National Vision Holdings (EYE) United States $2.120B 45.18
Aphria (APHA) $1.712B 0.00
Cardiovascular Systems (CSII) United States $1.377B 790.80
Phibro Animal Health (PAHC) United States $1.168B 17.50
AtriCure (ATRC) United States $1.136B 0.00
VAREX IMAGING (VREX) United States $1.083B 22.98
Lantheus Holdings (LNTH) United States $0.941B 25.00
NanoString Technologies (NSTG) United States $0.941B 0.00
Omeros (OMER) United States $0.914B 0.00
MacroGenics (MGNX) United States $0.913B 0.00
PetIQ (PETQ) United States $0.806B 19.58
Eagle Pharmaceuticals (EGRX) United States $0.753B 21.11
TG Therapeutics (TGTX) United States $0.609B 0.00
LeMaitre Vascular (LMAT) United States $0.541B 26.20
OraSure Technologies (OSUR) United States $0.529B 24.37
Surmodics (SRDX) United States $0.527B 76.59
Quanterix (QTRX) United States $0.498B 0.00
Meridian Bioscience (VIVO) United States $0.462B 14.13
Evolus (EOLS) United States $0.440B 0.00
BioLife Solutions (BLFS) United States $0.343B 107.18
Utah Medical Products (UTMD) United States $0.311B 21.52
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.310B 0.00
Vapotherm (VAPO) United States $0.282B 0.00
Rockwell Medical (RMTI) United States $0.267B 0.00
Zynex (ZYXI) United States $0.240B 24.80
Owens & Minor (OMI) United States $0.226B 4.79
Cytosorbents (CTSO) United States $0.223B 0.00
Bovie Medical (APYX) United States $0.204B 0.00
Chimerix (CMRX) United States $0.179B 0.00
Chembio Diagnostics (CEMI) United States $0.134B 0.00
Fonar (FONR) United States $0.134B 7.05
Surface Oncology (SURF) United States $0.111B 0.00
Female Health (VERU) United States $0.103B 0.00
United-Guardian (UG) United States $0.094B 20.70
Neurotrope (NTRP) United States $0.091B 0.00
Insys Therapeutics (INSY) United States $0.079B 0.00
Trinity Biotech (TRIB) Ireland $0.058B 20.00
Oramed Pharmaceuticals (ORMP) United States $0.053B 0.00
ImmuCell (ICCC) United States $0.045B 0.00
Senestech (SNES) United States $0.042B 0.00
GUARDION HEALTH (GHSI) United States $0.032B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.029B 0.00
BRAINSWAY LTD (BWAY) Israel $0.027B 0.00
Valeritas Holdings (VLRX) United States $0.025B 0.00
Capricor Therapeutics (CAPR) United States $0.011B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.011B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
Akers Biosciences Inc (AKER) United States $0.009B 0.00
NeuroMetrix (NURO) United States $0.006B 4.60